Allergic Conjunctivitis (AC) - Market Insights, Epidemiology and Market Forecast-2027

  • ID: 4520735
  • Drug Pipelines
  • 118 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 4

FEATURED COMPANIES

  • Nicox Pharma - Allergan
  • ORA, Inc. - Novartis
  • Santen Pharma - Medpointe
  • MORE
This report titled ‘Allergic Conjunctivitis (AC) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Allergic Conjunctivitis (AC) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Allergic Conjunctivitis (AC) - Disease Understanding and Treatment Algorithm:

The Allergic Conjunctivitis (AC) market report gives the thorough understanding of the Allergic Conjunctivitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Allergic Conjunctivitis in the US, Europe, and Japan.

Allergic Conjunctivitis Epidemiology:

The Allergic Conjunctivitis (AC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, diagnosed prevalent cases and sub-type specific prevalent cases) scenario of Allergic Conjunctivitis (AC) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to this research, the total number of diagnosed prevalent population of Allergic Conjunctivitis (AC) was found to be 64,945,428, in the year 2016.

Allergic Conjunctivitis Drug Chapters:

This segment of the Allergic Conjunctivitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, there are mainly eight therapeutic classes of drugs contributing towards the market size of AC - Decongestants/Antihistamines, Corticosteroids, Topical Histamines, Systemic Histamines, Mast cell stabilizers (MCS), Immunomodulators, Nonsteroidal anti-inflammatory drugs (NSAIDs) and Dual acting Antihistamines/Mast cell stabilizers. The approved (and their generic versions) as well as off-label &/or OTC (Over the counter) products are being used for the treatment of Allergic Conjunctivitis, belonging to these therapeutic classes only. Detailed chapter for upcoming therapies like OTX-DP (also known as dexamethasone insert) (Ocular Therapeutics), ADX-102 (Aldeyra Therapeutics), PRT2761 (Portola Pharmaceuticals) and Bilastine (Faes Farma) have been covered in the report.

Allergic Conjunctivitis Market Outlook:

The Allergic Conjunctivitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. Upcoming therapies such as Zerviate (Nicox Pharma; NDA approved in May 2017, launch planned in the fall season of 2018), ADX-102 (Aldeyra Therapeutics), PRT-2761 (ORA, Inc.), OTX-DP (Ocular Therapeutix, Inc), DE114A (Santen Pharma; Only in Japan) and Bilastine (Faes Farma) have the potential to create a significant positive shift in the Allergic Conjunctivitis market size.

According to this research, the market of Allergic Conjunctivitis in 7MM was found to be USD 1,582 million in 2016, and is expected to increase from 2016-2027.

Allergic Conjunctivitis Drugs Uptake:

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Allergic Conjunctivitis Report Insights:
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Allergic Conjunctivitis Report Key Strengths:
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Allergic Conjunctivitis Report Assessment:
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits:
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Allergic Conjunctivitis market
  • Organize sales and marketing efforts by identifying the best opportunities for Allergic Conjunctivitis market
  • To understand the future market competition in the Allergic Conjunctivitis market.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Nicox Pharma - Allergan
  • ORA, Inc. - Novartis
  • Santen Pharma - Medpointe
  • MORE
1. Key Insights

2. Allergic Conjunctivitis Market Overview at a Glance
2.1. Market Share (%) Distribution of Allergic Conjunctivitis in 2017
2.2. Market Share (%) Distribution of Allergic Conjunctivitis in 2027

3. Disease Background and Overview: Allergic Conjunctivitis (AC)
3.1. Introduction
3.2. Classification of Allergic Conjunctivitis
3.3. Causes
3.4. Risk factors
3.5. Symptoms
3.6. Pathophysiology
3.7. Diagnosis

4. Epidemiology and Patient Population

5. Key Findings
5.1. Population and Forecast Parameters
5.2. 7MM Total Diagnosed Prevalent Patient Population of Allergic Conjunctivitis

6. Country Wise-Epidemiology of Allergic Conjunctivitis
6.1. United States
6.1.1. Total Prevalent Patient Population of Allergic Conjunctivitis in the US
6.1.2. Sub-type Specific Prevalence of Allergic Conjunctivitis in the US
6.2. EU5 Countries
6.2.1. Germany
6.2.2. Total Prevalent Patient Population of Allergic Conjunctivitis in Germany
6.2.3. Sub-type Specific Prevalence of Allergic Conjunctivitis in Germany
6.2.4. France
6.2.5. Total Prevalent Patient Population of Allergic Conjunctivitis in France
6.2.6. Sub-type Specific Prevalence of Allergic Conjunctivitis in France
6.2.7. Italy
6.2.8. Total Prevalent Patient Population of Allergic Conjunctivitis in Italy
6.2.9. Sub-type Specific Prevalence of Allergic Conjunctivitis in Italy
6.2.10. Spain
6.2.11. Total Prevalent Patient Population of Allergic Conjunctivitis in Spain
6.2.12. Sub-type Specific Prevalence of Allergic Conjunctivitis in Spain
6.2.13. United Kingdom
6.2.14. Total Prevalent Patient Population of Allergic Conjunctivitis in the UK
6.2.15. Sub-type Specific Prevalence of Allergic Conjunctivitis in the UK
6.3. Japan
6.3.1. Total Prevalent Patient Population of Allergic Conjunctivitis in Japan
6.3.2. Sub-type Specific Prevalence of Allergic Conjunctivitis in the UK

7. Treatment Agorithm
7.1. American Guidelines on Allergic Conjunctivitis
7.2. European Guidelines: Treatment Algorithm for Allergic Conjunctivitis
7.3. Japanese Guidelines for Allergic Conjunctival diseases 2017

8. Unmet needs

9. Marketed Drugs
9.1. Marketed Drugs by Class
9.1.1. Decongestants/Antihistamines
9.1.2. Corticosteroids
9.1.3. Topical/Systemic antihistamines
9.1.4. Mast cell stabilizers
9.1.5. Non-steroidal anti-inflammatory disease (NSAIDs)
9.1.6. Immunomodulators
9.1.7. Dual acting Antihistamines/Mast cell stabilizers

10. Emerging Drugs
10.1. OTX-DP (Dexamethasone Insert): Ocular Therapeutics
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Regulatory Milestones
10.1.4. Clinical Development
10.1.5. Safety and Efficacy
10.1.6. Advantages and Disadvantages
10.2. ADX-102: Aldeyra Therapeutics
10.2.1. Drug Description
10.2.2. Product Profile
10.2.3. Regulatory Milestones
10.2.4. Clinical Development
10.2.5. Safety and Efficacy
10.2.6. Advantages and Disadvantages
10.3. PRT2761: Portola Pharmaceuticals
10.3.1. Drug Description
10.3.2. Product Profile
10.3.3. Regulatory Milestones
10.3.4. Clinical Development
10.3.5. Advantages and Disadvantages
10.4. Bilastine: FAES Farma
10.4.1. Drug Description
10.4.2. Product Profile
10.4.3. Regulatory Milestones
10.4.4. Clinical Development
10.4.5. Advantages and Disadvantages

11. Allergic Conjunctivitis: 7 Major Market Analysis
11.1. Market Size of Allergic Conjunctivitis in 7MM

12. Market Outlook by Country

13. the United States: Market Outlook
13.1. Total Market Size of Allergic Conjunctivitis
13.2. Allergic Conjunctivitis Market by Therapeutic Class
13.3. Market Size of Allergic Conjunctivitis by Emerging Therapies

14. EU-5 Countries: Market Outlook
14.1. Germany
14.1.1. Total Market Size of Allergic Conjunctivitis
14.1.2. Allergic Conjunctivitis Market by Therapeutic Class
14.1.3. Market Size of Allergic Conjunctivitis by Emerging Therapies
14.2. France
14.2.1. Total Market Size of Allergic Conjunctivitis
14.2.2. Allergic Conjunctivitis Market by Therapeutic Class
14.2.3. Market Size of Allergic Conjunctivitis by Emerging Therapies
14.3. United Kingdom
14.3.1. Total Market Size of Allergic Conjunctivitis
14.3.2. Allergic Conjunctivitis Market by Therapeutic Class
14.3.3. Market Size of Allergic Conjunctivitis by Emerging Therapies
14.4. Spain
14.4.1. Total Market Size of Allergic Conjunctivitis
14.4.2. Allergic Conjunctivitis Market by Therapeutic Class
14.4.3. Market Size of Allergic Conjunctivitis by Emerging Therapies
14.5. Italy
14.5.1. Total Market Size of Allergic Conjunctivitis
14.5.2. Allergic Conjunctivitis Market by Therapeutic Class
14.5.3. Market Size of Allergic Conjunctivitis by Emerging Therapies

15. Japan: Market Outlook
15.1. Total Market Size of Allergic Conjunctivitis
15.2. Allergic Conjunctivitis Market by Therapeutic Class
15.3. Market Size of Allergic Conjunctivitis by Emerging Therapies

16. Market Drivers

17. Market Barriers

18. Appendix

19. Report Methodology

20. Capabilities

21. Disclaimer

22. About the Publisher

List of Tables
Table 1: Characteristics of types of AC
Table 2: Risk factors for Allergic Conjunctivitis
Table 3: Clinical involvement of the ocular tissues in allergic eye disorders
Table 4: Grading of symptoms and severity (Based on ARIA Criteria)
Table 5: Total Prevalent Patient Population of Allergic Conjunctivitis in the 7MM (2016-2027)
Table 6: Total Prevalent Population of Allergic Conjunctivitis in the United States (2016-2027)
Table 7: Sub-type Specific Prevalence of Allergic Conjunctivitis in the United States (2016-2027)
Table 8: Total Prevalent Population of Allergic Conjunctivitis in Germany (2016-2027)
Table 9: Sub-type Specific Prevalence of Allergic Conjunctivitis in Germany (2016-2027)
Table 10: Total Prevalent Population of Allergic Conjunctivitis in France (2016-2027)
Table 11: Sub-type Specific Prevalence of Allergic Conjunctivitis in France (2016-2027)
Table 12: Total Prevalent Population of Allergic Conjunctivitis in Italy (2016-2027)
Table 13: Sub-type Specific Prevalence of Allergic Conjunctivitis in Italy (2016-2027)
Table 14: Total Prevalent Population of Allergic Conjunctivitis in Spain (2016-2027)
Table 15: Sub-type Specific Prevalence of Allergic Conjunctivitis in Spain (2016-2027)
Table 16: Total Prevalent Population of Allergic Conjunctivitis in the UK (2016-2027)
Table 17: Sub-type Specific Prevalence of Allergic Conjunctivitis in the United Kingdom (2016-2027)
Table 18: Total Prevalent Population of Allergic Conjunctivitis in Japan (2016-2027)
Table 19: Sub-type Specific Prevalence of Allergic Conjunctivitis in Japan (2016-2027)
Table 20: Algorithm for the management of seasonal allergic conjunctivitis
Table 21: American Guidelines for AC treatment
Table 22: Topical medications for Seasonal Allergic Conjunctivitis
Table 23: Treatment of Allergic Conjunctival diseases 2017
Table 24: Antiallergic eye drops, steroid eye drops and steroid ointments used in Allergic conjunctivitis in Japan
Table 25: OTX-DP, Clinical Trial Description, 2018
Table 26: ADX-102, Clinical Trial Description, 2018
Table 27: PRT2761, Clinical Trial Description, 2018
Table 28: Bilastine, Clinical Trial Description, 2018
Table 29: 7 Major Market Size of Allergic Conjunctivitis in USD Million (2016-2027)
Table 30: 7 Major Market Size of Allergic Conjunctivitis in USD Million (2016-2027)
Table 31: the U.S. Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Table 32: Emerging Therapies market size of Allergic Conjunctivitis in USD Million (2016-2027)
Table 33: Market Size of Allergic Conjunctivitis in Germany, in USD Million (2016-2027)
Table 34: Germany Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Table 35: Emerging Therapies market of Allergic Conjunctivitis in Germany, in USD Million (2016-2027)
Table 36: Market Size of Allergic Conjunctivitis in France, in USD Million (2016-2027)
Table 37: France Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Table 38: Emerging Therapies market of Allergic Conjunctivitis in France, in USD Million (2016-2027)
Table 39: Market Size of Allergic Conjunctivitis in the UK, in USD Million (2016-2027)
Table 40: UK Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Table 41: Emerging Therapies market of Allergic Conjunctivitis in the UK, in USD Million (2016-2027)
Table 42: Market Size of Allergic Conjunctivitis in Spain, in USD Million (2016-2027)
Table 43: Spain Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Table 44: Emerging Therapies market of Allergic Conjunctivitis in Spain, in USD Million (2016-2027)
Table 45: Market Size of Allergic Conjunctivitis in Italy, in USD Million (2016-2027)
Table 46: Italy Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Table 47: Emerging Therapies market of Allergic Conjunctivitis in Italy, in USD Million (2016-2027)
Table 48: Market Size of Allergic Conjunctivitis in Japan, in USD Million (2016-2027)
Table 49: Japan Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Table 50: Emerging Therapies market of Allergic Conjunctivitis in Japan, in USD Million (2016-2027)

List of Figures
Figure 1: Classification of Allergic Conjunctivitis
Figure 2: Symptoms of Allergic Conjunctivitis
Figure 3: the early and late phase of ocular allergic reactions
Figure 4: Total Diagnosed Prevalent Patient Population of Allergic Conjunctivitis in the 7MM (2016-2027)
Figure 5: Prevalence of Allergic Conjunctivitis in the United States (2016-2027)
Figure 6: Sub-type Specific Prevalence of Allergic Conjunctivitis in the United States (2016-2027)
Figure 7: Total Prevalent Population of Allergic Conjunctivitis in Germany (2016-2027)
Figure 8: Sub-type Specific Prevalence of Allergic Conjunctivitis in Germany (2016-2027)
Figure 9: Total Prevalent Population of Allergic Conjunctivitis in France (2016-2027)
Figure 10: Sub-type Specific Prevalence of Allergic Conjunctivitis in France (2016-2027)
Figure 11: Total Prevalent Population of Allergic Conjunctivitis in Italy (2016-2027)
Figure 12: Sub-type Specific Prevalence of Allergic Conjunctivitis in Italy (2016-2027)
Figure 13: Total Prevalent Population of Allergic Conjunctivitis in Spain (2016-2027)
Figure 14: Sub-type Specific Prevalence of Allergic Conjunctivitis in Spain (2016-2027)
Figure 15: Total Prevalent Population of Allergic Conjunctivitis in the UK (2016-2027)
Figure 16: Sub-type Specific Prevalence of Allergic Conjunctivitis in the United Kingdom (2016-2027)
Figure 17: Total Prevalent Population of Allergic Conjunctivitis in Japan (2016-2027)
Figure 18: Sub-type Specific Prevalence of Allergic Conjunctivitis in Japan (2016-2027)
Figure 19: Treatment of Allergic Conjunctivitis (AC): Proliferative (vernal keratoconjunctivitis)
Figure 20: Primary treatment of Acute and Chronic forms of Allergic conjunctivitis
Figure 21: Secondary treatment of Acute and Chronic forms of AC
Figure 22: Tertiary treatment of acute and chronic forms of ocular allergy
Figure 23: Treatment of Allergic Conjunctivitis (AC): Proliferative (vernal keratoconjunctivitis)
Figure 24: Unmet Needs of Allergic Conjunctivitis (AC)
Figure 25: 7 Major Market Size of Allergic Conjunctivitis in USD Million (2016-2027)
Figure 26: Market Size of Allergic Conjunctivitis in the United States, USD Millions (2016-2027)
Figure 27: the U.S. Allergic Conjunctivitis Market by Therapeutic Class in USD Million (2016-2027)
Figure 28: the U.S. Emerging Therapies market size of Allergic Conjunctivitis in USD Million (2016-2027)
Figure 29: Market Size of Allergic Conjunctivitis in Germany, USD Millions (2016-2027)
Figure 30: Allergic Conjunctivitis Market by Therapeutic Class in Germany, in USD Million (2016-2027)
Figure 31: Emerging Therapies market of Allergic Conjunctivitis in Germany, in USD Million (2016-2027)
Figure 32: Market Size of Allergic Conjunctivitis in France, USD Millions (2016-2027)
Figure 33: Allergic Conjunctivitis Market by Therapeutic Class in France, in USD Million (2016-2027)
Figure 34: Emerging Therapies market of Allergic Conjunctivitis in France, in USD Million (2016-2027)
Figure 35: Market Size of Allergic Conjunctivitis in the UK, USD Millions (2016-2027)
Figure 36: Allergic Conjunctivitis Market by Therapeutic Class in the UK, in USD Million (2016-2027)
Figure 37: Emerging Therapies market of Allergic Conjunctivitis in the UK, in USD Million (2016-2027)
Figure 38: Market Size of Allergic Conjunctivitis in Spain, USD Millions (2016-2027)
Figure 39: Allergic Conjunctivitis Market by Therapeutic Class in Spain, in USD Million (2016-2027)
Figure 40: Emerging Therapies market of Allergic Conjunctivitis in Spain, in USD Million (2016-2027)
Figure 41: Market Size of Allergic Conjunctivitis in Italy, USD Millions (2016-2027)
Figure 42: Allergic Conjunctivitis Market by Therapeutic Class in Italy, in USD Million (2016-2027)
Figure 43: Emerging Therapies market of Allergic Conjunctivitis in Italy, in USD Million (2016-2027)
Figure 44: Market Size of Allergic Conjunctivitis in Japan, USD Millions (2016-2027)
Figure 45: Allergic Conjunctivitis Market by Therapeutic Class in Japan, in USD Million (2016-2027)
Figure 46: Emerging Therapies market of Allergic Conjunctivitis in Japan, in USD Million (2016-2027)
Figure 47: Market Drivers
Figure 48: Market Barriers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Nicox Pharma - Allergan
  • Aldeyra Therapeutics - Valeant
  • ORA, Inc. - Novartis
  • Ocular Therapeutix, Inc. - Pfizer
  • Santen Pharma - Medpointe
  • Faes Pharma - Bausche & Lombe
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll